Evidence map›Paper›PMID 41512214›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2026

Precision Oncology 2.0: Guiding Magic Bullets With Expression-Based Liquid Biopsy.

Gunsagar S Gulati, Toni K Choueiri, Matthew L Freedman, Sylvan C Baca

Abstract read
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Variable cellular and radiobiological effects of [Journal of experimental & clinical cancer research : CR · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Gunsagar S GulatiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0003-2798-6220
Toni K ChoueiriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-9201-3217
Matthew L FreedmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-0151-1238
Sylvan C BacaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-4087-8606

Funding

Physician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1M
Molecular Determinants of Response and Resistance to EZH2 and PARP inhibition in Prostate CancerP50CA272390 · NCI · DANA-FARBER CANCER INST · PI Steven P. Balk, Himisha Beltran · 2023 to 2026
$12.0M
Elucidation of the genetic mechanisms driving prostate tumorigenesis through integrative computational and functional approachesR01CA251555 · NCI · DANA-FARBER CANCER INST · PI FREEDMAN, MATTHEW L, PASANIUC, BOGDAN · 2021 to 2025
$3.4M
Elucidating prostate cancer risk mechanisms through large-scale cistrome wide association studiesR01CA262577 · NCI · DANA-FARBER CANCER INST · PI FREEDMAN, MATTHEW L, GIMELBRANT, ALEXANDER · 2022 to 2025
$3.3M
Common biology underlying pleiotropic breast, prostate and ovarian cancer risk lociR01CA259058 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI MATTHEW L FREEDMAN, Simon Andrew Gayther · 2022 to 2026
$2.5M
Characterizing genetic risk of cancer across diverse populations through multi-ancestry epigenome profiling and chromatin QTL discoveryU01CA296432 · NCI · DANA-FARBER CANCER INST · PI Sylvan C. Baca · 2025 to 2026
$1.4M
Mapping the epigenetic dynamics of prostate cancer progression: integrating liquid biopsies and single-cell epigenomics for early detection of lineage plasticity and clinical decision-makingR01CA300092 · NCI · DANA-FARBER CANCER INST · PI Andre M Bergman, MATTHEW L FREEDMAN · 2025 to 2026
$1.2M
NCI NIH HHS P50 CA272390NCI NIH HHS R01 CA251555NCI NIH HHS R01 CA259058NCI NIH HHS R01 CA262577NCI NIH HHS R01 CA300092NCI NIH HHS T32 CA009172NCI NIH HHS U01 CA296432
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41512214
PMCPMC12795309

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.